1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL.V
Vaxil Bio Ltd.CA flagToronto Stock Exchange Ventures
0.16
CAD
-0.03
- -
425,061.00Market Cap
Vaxil Bio Ltd.
VXL.V
(Toronto Stock Exchange Ventures)

Recent

price

0.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-31.26
-33.4
-22.5
-4.72
-6.51
-4.33
-5.76
-1.79
-0.61
-0.65
-0.67
-0.36
-0.21
-0.09
-0.06
0.18
0.15
Basic EPS, GAAP
-32.93
-31.49
-8.63
-5.98
-1.43
-2.52
-1.9
-0.99
-0.55
-0.34
-0.62
-0.4
-0.27
-0.2
-0.07
-0.06
-0.08
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-44.74
9.73
-71.33
-25.86
-24.46
-10.2
-3.34
-4.07
-2.28
-2.8
-1.81
-0.9
-1.11
-1.2
-1.26
-1.02
-0.95
Book Value per Share
58.32
16.98
3.79
2.93
0.38
-0.88
0.83
-0.48
0.26
-0.33
0.4
0.62
0.41
0.33
0.26
0.48
0.4
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
1
1
2
2
2
3
3
3
3
3
3
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
- -
- -
-1
-1
-5
-2
-1
-1
-1
-1
-1
- -
- -
1
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
1
-1
- -
-1
1
2
1
1
1
1
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
- -
- -
- -
- -
- -
1
- -
- -
-1
1
2
1
1
1
1
1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-17.2
-23.34
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-16.45
-14.87
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
4
4
Market Capitalization
1
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-111.01%
25.54%
90.64%
Free Cash Flow
2.41%
-30.55%
-15.96%
Net Income, GAAP
-29.91%
-109.57%
-393.26%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.02
- -
-0.06
2025
-0.03
0.02
-0.01
- -
0.18
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Mustang Bio, Inc. (MBIO)
Clal Biotechnology Industries Ltd. (CBI.TA)
Novavax, Inc. (NVAX)
Orphazyme A/S (ORPH)
TaiMed Biologics Inc. (4147.TWO)
GenMont Biotech Incorporation (3164.TW)
Business
Vaxil Bio Ltd. (TSXV: VXL) is a Canada-based biotechnology company focused on a novel drug discovery and development platform based on signal peptides (SPs) to target cancer and infectious diseases. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase I/II clinical trial for multiple myeloma treatment and received orphan drug status from the FDA and EMA; monoclonal antibody candidates including SPmAb2 and SPmAb6 for oncology and infectious diseases; MTbuVax, a tuberculosis vaccine/treatment candidate; and a SP-based COVID-19 vaccine candidate, along with P-Esbp-DOX, a drug delivery polymer targeting E-selectin licensed from BGN Technologies. Founded in 2006 and headquartered in Toronto, Ontario, with operations linked to Rehovot, Israel, Vaxil Bio Ltd. primarily serves the immuno-oncology and infectious disease markets through its proprietary VaxHit bioinformatic platform that identifies universal neoantigens. In August 2024, the company entered a definitive amalgamation agreement with Green Data Centers for a reverse takeover and change of business to data center development, which was subsequently terminated, with Green Data Centers required to repay a related loan by July 2025; it also completed a 1-for-50 reverse stock split effective May 15, 2025, and announced a non-brokered private placement update in November 2025 to explore capital sources for ongoing SP platform advancements.